• Explore /
  • Poster
  • / Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.

Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.

Abstract Video & Slides Poster

Authors

null

Celeste Lebbe

APHP Dermatology and CIC, U976, Université de Paris, Hôpital Saint-Louis, Paris, France

Celeste Lebbe , Nicolas Meyer , Laurent Mortier , Ivan Marquez-Rodas , Caroline Robert , Piotr Rutkowski , Marcus O. Butler , Thomas Eigentler , Alexander M. Menzies , Michael Smylie , Ana Maria Arance , Paolo Antonio Ascierto , Inge Marie Svane , Mazhar Ajaz , Nikhil I. Khushalani , Maurice Lobo , Jesus Zoco , Jacopo Pigozzo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02714218

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9516)

DOI

10.1200/JCO.2021.39.15_suppl.9516

Abstract #

9516

Abstract Disclosures

Similar Posters

First Author: Dirk Schadendorf

First Author: F. Stephen Hodi

First Author: Hamid Emamekhoo

First Author: Scott S. Tykodi